Article

Prevention of venous thromboembolism after ischemic stroke.

Department of Neurology, Boston Medical Center, Boston, Massachusetts 02118, USA.
Current opinion in pulmonary medicine (Impact Factor: 2.96). 10/2008; 14(5):389-96. DOI: 10.1097/MCP.0b013e328307ee24
Source: PubMed

ABSTRACT Venous thromboembolism is an important cause of morbidity and mortality after stroke. Its potential for prevention is substantial with the use of antithrombotic agents, but there is no agreement on the relative advantages and disadvantages of various available prophylactic drugs. There have been recent publications that clarify some of these issues.
Data from recently published controlled clinical trials have added to our understanding of the risk-benefit ratio of the two most commonly used antithrombotics: unfractionated heparin and low-molecular-weight heparins. These data suggest that the low-molecular-weight heparin enoxaparin has a superior clinical profile in comparison with unfractionated heparin.
Antithrombotic agents are the mainstay in the prevention of venous thromboembolism after stroke. The highly effective unfractionated heparin and low-molecular-weight heparins may have a different clinical profile that could have a substantial impact in clinical practice.

0 Followers
 · 
77 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effect of Osteoking ( masculine(1)i) in preventing postoperational deep venous thrombosis (DVT) in patients with intertrochanteric fracture (ITF). With prospective and randomized controlled clinical design adopted, 62 patients with ITF after operation were assigned into 2 groups, the tested group and the control group, Osteoking (25 ml every other day) and Sanchi-dansheng tablets (3 tablets thrice a day) were given orally to them respectively for 10 days. Difference of round length of thighs and shanks between two sides were measured on the 10th day and Doppler ultrasonic examination on the fractured leg was carried out. The occurrence rate of DVT in the tested group was 9.4%, which was lower than that in the control group (30.0%, P < 0.05). All the difference of round lengths, either that of the thigh or the shank, was less in the tested group than that in the control group, showing statistical significance (P < 0.05). Osteoking has a satisfactory effect in preventing postoperational DVT in patients with ITF.
    Chinese Journal of Integrative Medicine 01/2006; 11(4):297-9. DOI:10.1007/BF02835793 · 1.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low-molecular-weight heparins (LMWHs) are very important drugs; unfortunately, the routine global hemostasis assays activated partial thromboplastin time and prothrombin time are not sensitive to LMWHs. Here the 50% inhibitory concentration (IC(50)) values of heparin and LMWHs on extrinsic thrombin generation are determined. Pooled normal plasma was supplemented with 0-2 IU/ml unfractionated heparin, 0-2 IU/ml LMWH dalteparin, or 0-20 microg/ml pentosanpolysulfate in 5-ml polystyrole tubes (23 degrees C) and tested in the tissue-factor-triggered extrinsic coagulation activity assay (EXCA): 50 microl plasma + 5 microl tissue factor/CaCl(2), 1 and 2 min incubation time at 37 degrees C (coagulation reaction time for EXCA-1 and EXCA-2); + 100 microl of 2.5 mol/l arginine (pH 8.6), 20 min at room temperature; + 50 microl of 1 mmol/l CHG-Ala-Arg-pNA, 1.25 mol/l arginine; increase in absorbance/time at 23 degrees C; calibrator = 1 IU/ml bovine thrombin in 6.7% human albumin replacing the plasma sample; in EXCA-1, about 1 IU/ml thrombin is generated in pooled unfrozen normal citrated plasma. The IC(50) values in EXCA-1 are 0.1 IU/ml heparin, 0.02 IU/ml LMWH, and 4.7 microg/ml pentosanpolysulfate. In ECXA-2 the IC(50) values are 0.07 IU/ml, 0.01 IU/ml, and 4.6 microg/ml, respectively. The EXCA reflects the efficiency of anticoagulants on plasmatic coagulation. It is suggested to adjust the dosage of LMWH according to the EXCA value; about 30% of normal extrinsic thrombin generation might be the correct dose for prophylactic anticoagulation.
    Blood Coagulation and Fibrinolysis 12/2006; 17(8):633-7. DOI:10.1097/01.mbc.0000252596.79282.5d · 1.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Massive pulmonary embolism is a life-threatening condition to be treated with anticoagulants or even thrombolytic agents in selected cases. However, these drugs are controindicated after a recent hemorrhagic episode. We report the case of a 46-year-old patient with uncontrolled systemic hypertension who was affected by severe spontaneous cerebral hemorrhage and left hemiparesis. After some days of rehabilitation care he developed sudden dyspnea, tachycardia and hypotension secondary to bilateral pulmonary embolism. Owing to controindication to the use of thrombolytic agents, anticoagulant therapy with high-dose intravenous unfractionated heparin followed by oral warfarin was begun, with a successful and uncomplicated outcome. The therapeutic approach to similar not uncommon cases is debated and some hypotheses are made about the aetiology of pulmonary embolism in these patients.
    Journal of Thrombosis and Thrombolysis 05/2008; 25(2):231-4. DOI:10.1007/s11239-007-0053-5 · 2.17 Impact Factor
Show more